← Leaderboards
Eric R Prossnitz
University Of New Mexico
$16,113,550
Attributed
$21,446,943
Total exposure
17
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$21,446,943 · 17
By mechanism
R01$14,952,574 · 8
UT2$3,188,645 · 1
U54$1,791,538 · 2
P20$920,066 · 2
P30$518,682 · 3
R03$75,438 · 1
Top collaborators
- Jeffrey B Arterburn18 shared
- Tudor I Oprea9 shared
- John Chavez3 shared
- Robert Gregory Delcampo3 shared
Most similar at University Of New Mexico
Same institution · by research overlap
- Cheryl L Willman$57,213,396
- Tudor I Oprea$13,526,508
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsSignal TransductionEstrogen ReceptorsReceptorAgonistMediatingLigandsFundingMalignant Breast NeoplasmWomanSmall MoleculeEstrogensNew MexicoUniversitiesPhysiologyHormonesEndometrial CarcinomaIn VivoGtp-Binding ProteinsMolecularLeadGrowthTherapeutic AgentsEstrogen Antagonists
Grant awards (77)
Molecular Mechanisms and Applications of Novel ER/GPER-selective Ligands$1,024,823
R01 · FY2025 · CA · contact PI
Cancer Therapeutics$70,695
P30 · FY2025 · CA · contact PI
Development of an Educational Product for Accelerating Solutions for Commercialization and Entrepreneurial Development (ASCEND) in Western IDeA States$1,463,014
UT2 · FY2024 · GM
Molecular Mechanisms and Applications of Novel ER/GPER-selective Ligands$486,792
R01 · FY2024 · CA · contact PI
Cancer Therapeutics$70,695
P30 · FY2024 · CA · contact PI
Development of an Educational Product for Accelerating Solutions for Commercialization and Entrepreneurial Development (ASCEND) in Western IDeA States$1,479,976
UT2 · FY2023 · GM
Molecular Mechanisms and Applications of Novel ER/GPER-selective Ligands$502,165
R01 · FY2023 · CA · contact PI
G protein-coupled estrogen receptor GPER and breast carcinogenesis$191,101
R01 · FY2023 · CA · contact PI
Cancer Therapeutics$70,697
P30 · FY2023 · CA · contact PI
Molecular Mechanisms and Applications of Novel ER/GPER-selective Ligands$525,537
R01 · FY2022 · CA · contact PI
G protein-coupled estrogen receptor GPER and breast carcinogenesis$346,862
R01 · FY2022 · CA · contact PI
Development of an Educational Product for Accelerating Solutions for Commercialization and Entrepreneurial Development (ASCEND) in Western IDeA States$245,655
UT2 · FY2022 · GM
Cancer Therapeutics$70,510
P30 · FY2022 · CA · contact PI
G protein-coupled estrogen receptor GPER and breast carcinogenesis$353,942
R01 · FY2021 · CA · contact PI
Molecular Mechanisms and Applications of Novel ER/GPER-selective Ligands$320,000
R01 · FY2020 · CA · contact PI
G protein-coupled estrogen receptor GPER and breast carcinogenesis$158,942
R01 · FY2020 · CA · contact PI
Inflammation and Metabolism Core$143,616
P20 · FY2020 · GM · contact PI
G protein-coupled estrogen receptor GPER and breast carcinogenesis$343,324
R01 · FY2019 · CA · contact PI
Molecular Mechanisms and Applications of Novel ER/GPER-selective Ligands$310,400
R01 · FY2019 · CA · contact PI
Inflammation and Metabolism Core$216,796
P20 · FY2019 · GM · contact PI
G protein-coupled estrogen receptor GPER and breast carcinogenesis$353,942
R01 · FY2018 · CA · contact PI
Molecular Mechanisms and Applications of Novel ER/GPER-selective Ligands$320,000
R01 · FY2018 · CA · contact PI
Inflammation and Metabolism Core$252,515
P20 · FY2018 · GM · contact PI
Molecular Mechanisms and Applications of Novel ER/GPER-selective Ligands$320,000
R01 · FY2017 · CA · contact PI
Inflammation and Metabolism Core$307,139
P20 · FY2017 · GM · contact PI
Molecular Mechanisms and Applications of Novel ER/GPER-selective Ligands$320,000
R01 · FY2016 · CA · contact PI
G protein-coupled estrogen receptor GPER and breast carcinogenesis$313,325
R01 · FY2016 · CA · contact PI
G protein-coupled estrogen receptor GPER and breast carcinogenesis$313,325
R01 · FY2015 · CA · contact PI
G protein-coupled estrogen receptor GPER and breast carcinogenesis$303,925
R01 · FY2014 · CA · contact PI
Womens Cancers Research Program$39,023
P30 · FY2014 · CA · contact PI
G protein-coupled estrogen receptor GPER and breast carcinogenesis$294,526
R01 · FY2013 · CA · contact PI
Womens Cancers Research Program$37,956
P30 · FY2013 · CA · contact PI
Womens Cancers Research Program$6,251
P30 · FY2013 · CA · contact PI
G protein-coupled estrogen receptor GPER and breast carcinogenesis$313,325
R01 · FY2012 · CA · contact PI
Development of GPR30-Selective Ligands$300,749
R01 · FY2012 · CA · contact PI
Assay Implementation$98,311
U54 · FY2012 · MH · contact PI
Womens Cancers Research Program$40,967
P30 · FY2012 · CA · contact PI
MLP Assay for Arrestin-AP2 Inhibitors$37,750
R03 · FY2012 · DA · contact PI
Development of GPR30-Selective Ligands$19,934
R01 · FY2012 · CA · contact PI
Womens Cancers Research Program$7,778
P30 · FY2012 · CA · contact PI
Womens Cancers Research Program$4,166
P30 · FY2012 · CA · contact PI
Assay Implementation$441,132
U54 · FY2011 · MH · contact PI
Development of GPR30-Selective Ligands$300,749
R01 · FY2011 · CA · contact PI
Development of GPR30-Selective Ligands$52,552
R01 · FY2011 · CA · contact PI
Womens Cancers Research Program$47,023
P30 · FY2011 · CA · contact PI
MLP Assay for Arrestin-AP2 Inhibitors$37,688
R03 · FY2011 · DA · contact PI
Assay Implementation$434,225
U54 · FY2010 · MH · contact PI
Development of GPR30-Selective Ligands$310,051
R01 · FY2010 · CA · contact PI
A novel intracellular 7TM estrogen receptor in breast$258,530
R01 · FY2010 · CA · contact PI
Womens Cancers Research Program$52,921
P30 · FY2010 · CA · contact PI
Development of GPR30-Selective Ligands$52,637
R01 · FY2010 · CA · contact PI
Assay Implementation$400,355
U54 · FY2009 · MH · contact PI
Development of GPR30-Selective Ligands$310,051
R01 · FY2009 · CA · contact PI
The Role of GPR30 in Advanced Endometrial Cancer$285,000
R01 · FY2009 · CA · contact PI
A novel intracellular 7TM estrogen receptor in breast$258,530
R01 · FY2009 · CA · contact PI
Development of GPR30-Selective Ligands$44,883
R01 · FY2009 · CA · contact PI
Assay Implementation$417,515
U54 · FY2008 · MH · contact PI
Development of GPR30-Selective Ligands$322,551
R01 · FY2008 · CA · contact PI
The Role of GPR30 in Advanced Endometrial Cancer$285,000
R01 · FY2008 · CA · contact PI
A novel intracellular 7TM estrogen receptor in breast$258,530
R01 · FY2008 · CA · contact PI
The Role of GPR30 in Advanced Endometrial Cancer$285,000
R01 · FY2007 · CA · contact PI
Arrestin activation probed with mass spectrometry$268,810
R01 · FY2007 · GM · contact PI
A novel intracellular 7TM estrogen receptor in breast$258,530
R01 · FY2007 · CA · contact PI
Arrestin activation probed with mass spectrometry$276,838
R01 · FY2006 · GM · contact PI
A novel intracellular 7TM estrogen receptor in breast$266,250
R01 · FY2006 · CA · contact PI
Regulation of Chemoattractant Receptor Activation$336,600
R01 · FY2005 · AI
Arrestin activation probed with mass spectrometry$283,500
R01 · FY2005 · GM
Regulation of Chemoattractant Receptor Activation$336,635
R01 · FY2004 · AI
Arrestin activation probed with mass spectrometry$300,300
R01 · FY2004 · GM
Regulation of Chemoattractant Receptor Activation$336,668
R01 · FY2003 · AI
Regulation of Chemoattractant Receptor Activation$336,700
R01 · FY2002 · AI
MECHANISMS OF LEUKOCYTE ACTIVATION AND CHEMOTAXIS$326,983
R01 · FY2002 · AI
KINETIC MODELS OF LIGAND RECEPTOR G PROTEIN INTERCTIONS$0
P20 · FY2002 · GM
Regulation of Chemoattractant Receptor Activation$319,895
R01 · FY2001 · AI
MECHANISMS OF LEUKOCYTE ACTIVATION AND CHEMOTAXIS$242,046
R01 · FY2001 · AI
MECHANISMS OF LEUKOCYTE ACTIVATION AND CHEMOTAXIS$66,819
R01 · FY2001 · AI
MECHANISMS OF LEUKOCYTE ACTIVATION AND CHEMOTAXIS$234,997
R01 · FY2000 · AI